Ferring bets on Gameto’s reproductive health solution through $1.38bn takeover
Swiss pharma company Ferring Pharmaceuticals has agreed to acquire startup Gameto for up to $1.38bn as the company looks to…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal
Astellas Pharma has inked a billion-dollar licensing deal with Australian biotech, Audax Biosciences, which will see the company secure access…
-
Anthropic plots IPO amid ongoing foray into drug development
Artificial intelligence (AI) specialist Anthropic has detailed its plans to dive deeper into the world of drug discovery and development…
-
Pfizer’s prostate cancer combo moves to earlier line on expanded US approval
The US Food and Drug Administration (FDA) has awarded a label expansion to Pfizer’s targeted oncology combination of Talzenna (talazoparib)…
-
Gilead spends $1.28bn on PepStar’s potential Icotyde rival
Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23…
-
Building the next generation of sustainable data centres in pharma
In the age of AI, pharma and tech companies are increasingly joining forces. Inevitably, such collaboration demands a strong digital…
-
AstraZeneca bags another US indication for Ultomiris with IgAN approval
AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval…
-
EyePoint halves workforce and ends Phase III trial early after endpoint miss
EyePoint Pharmaceuticals has announced sweeping job cuts after its eye disease candidate, duravyu, failed to meet its key goal during…
-
Ambrose Healthcare fortifies rare disease pipeline on AM-Pharma takeover
Ambrose Healthcare has acquired 100% of Dutch pharma company AM-Pharma’s shares, absorbing the company and fortifying its pipeline with a…
-
Roche’s Enspryng nets a second indication on FDA eye disease approval
The US Food and Drug Administration (FDA) has granted Roche a label expansion for its ophthalmology therapy, Enspryng (satralizumab), in…